OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY release_cwseboeplfasxpc2vsnfjjnjia [as of editgroup_ybxoyfqlh5fkjnpljbl6tfeqh4]

by Christopher T. Ritchlin, Arthur Kavanaugh, Joseph F. Merola, Georg Schett, Jose U. Scher, Richard B. Warren, Deepak Assudani, Thomas Kumke, Barbara Ink, Iain Mcinnes

Released as a paper-conference by BMJ Publishing Group Ltd and European League Against Rheumatism
Release Year 2019
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
Type  paper-conference
Stage   unknown
Year   2019
Work Entity
grouping other versions (eg, pre-print) and variants of this release
Accepted Edit Version

This is the version of the entity as of a specific merged editgroup: ybxoyfqlh5fkjnpljbl6tfeqh4